Cortisporin Shortage: What Providers and Prescribers Need to Know in 2026

Cortisporin Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Cortisporin prescriptions, you're not alone. Across the country, pharmacies are telling patients that Cortisporin Otic (Neomycin/Polymyxin B/Hydrocortisone) is "out of stock" or "unavailable." This briefing covers the current supply landscape, prescribing considerations, and tools to help your patients access treatment without delays.

Current Supply Status

As of early 2026, Cortisporin is not on the FDA's official drug shortage list. The product has not been discontinued, and generic Neomycin/Polymyxin B/Hydrocortisone otic suspension continues to be manufactured by multiple companies.

The access challenges are pharmacy-level, not manufacturing-level. Key factors include:

• Low routine stocking: Cortisporin is a niche otic product with episodic, seasonal demand. Many chain pharmacies don't maintain regular inventory.
• Wholesaler allocation practices: When individual generic manufacturers experience temporary production delays, wholesalers may allocate limited quantities, affecting pharmacies that rely on a single distribution channel.
• Brand vs. generic dispensing: Prescriptions written for "Cortisporin" (brand) rather than the generic may trigger availability issues, since the brand product is stocked far less frequently.

Timeline and Context

Cortisporin has been on the market for decades, originally manufactured by Burroughs Wellcome and later by Monarch Pharmaceuticals and Endo Pharmaceuticals. Generic versions have been available for many years, and the market is served by multiple generic manufacturers.

There has been no formal FDA-reported shortage event specific to Neomycin/Polymyxin B/Hydrocortisone otic products in recent years. The perceived shortage is driven by:

• Declining pharmacy shelf space for low-volume specialty products
• Consolidation among generic manufacturers
• Seasonal demand spikes (summer otitis externa season)
• Patient confusion between Cortisporin Otic and Cortisporin-TC Otic (a different, brand-only formulation)

Prescribing Implications

The stocking challenges with Cortisporin have several practical implications for your prescribing workflow:

Generic Substitution

Writing prescriptions for "Neomycin/Polymyxin B/Hydrocortisone otic suspension" rather than "Cortisporin" and allowing generic substitution significantly increases fill rates. The generic is therapeutically equivalent and far more widely stocked.

Tympanic Membrane Considerations

Cortisporin Otic is contraindicated with perforated tympanic membranes due to ototoxicity risk from Neomycin. For patients with ear tubes, tympanic membrane perforations, or chronic otitis media with drainage, fluoroquinolone-based alternatives (Ofloxacin Otic, Ciprodex) are the appropriate first-line choice regardless of Cortisporin availability.

Neomycin Sensitization

Neomycin is one of the most common contact sensitizers, with prevalence rates of 1-6% in the general population and higher in patients with chronic dermatitis. Consider this when prescribing Cortisporin for patients with eczema or a history of topical antibiotic reactions. Fluoroquinolone alternatives avoid this risk entirely.

Antibiotic Stewardship

For mild otitis externa, consider whether an antibiotic-steroid combination is necessary. Acetic Acid/Hydrocortisone (VoSol HC) provides an acidifying environment that inhibits bacterial growth without contributing to antibiotic resistance, and may be appropriate for mild cases or prophylaxis.

Availability Picture

Based on current market data, here is the relative availability of Cortisporin and common alternatives:

• Generic Neomycin/Polymyxin B/Hydrocortisone Otic: Available from multiple manufacturers. Most pharmacies can order within 1-2 business days if not in stock. Widely available at independent pharmacies.
• Brand Cortisporin Otic: Rarely stocked. Special order only at most locations.
• Cortisporin-TC Otic: Brand-only (Endo Pharmaceuticals), no generic available. Very limited stocking, $234-$350 per 10 mL bottle.
• Ofloxacin Otic (generic): Widely stocked, multiple manufacturers, excellent availability.
• Ciprodex (brand): Widely stocked at chain pharmacies, high cost but manufacturer savings programs available.

Cost and Access Considerations

Understanding the cost landscape helps you make prescribing decisions that balance clinical appropriateness with patient access:

• Generic Cortisporin Otic: $90-$170 retail; $26-$52 with discount coupons (GoodRx, SingleCare)
• Ofloxacin Otic (generic): $15-$40 — the most affordable option
• Ciprodex: $300+ retail; manufacturer savings programs available
• Cipro HC Otic: $350+ retail; brand-only
• VoSol HC (generic): $30-$80

For uninsured or underinsured patients, directing them to savings resources for Cortisporin can make a meaningful difference. Endo Pharmaceuticals has historically offered a patient assistance program, and programs like NeedyMeds and RxAssist can help identify additional support.

Tools and Resources for Your Practice

Medfinder for Providers offers real-time pharmacy availability data that can help your practice and patients locate Cortisporin and other medications in stock. Key features include:

• Real-time stock checks across local pharmacies
• Price comparison tools
• Alternative medication information

Integrating a stock-check step into your prescribing workflow — especially for niche medications like Cortisporin — can reduce patient callbacks, improve fill rates, and decrease time to treatment.

For detailed guidance on helping patients navigate availability challenges, see our companion guide: How to Help Your Patients Find Cortisporin in Stock.

Looking Ahead

The Cortisporin availability landscape is unlikely to change significantly in the near term. The product occupies a stable but niche market position with adequate generic competition. Key trends to watch include:

• Fluoroquinolone otic dominance: Ofloxacin and Ciprofloxacin-based ear drops continue to gain prescribing share due to once or twice-daily dosing, safety with perforated eardrums, and lower sensitization risk.
• Generic price stability: With multiple generic manufacturers in the market, pricing for Neomycin/Polymyxin B/Hydrocortisone otic products is expected to remain stable.
• Pharmacy stocking consolidation: As chain pharmacies continue to optimize inventory, low-volume specialty products may become even harder to find at walk-in locations, increasing the importance of real-time stock-checking tools.

Final Thoughts

Cortisporin remains a clinically useful product for otitis externa in patients with intact tympanic membranes. The current access challenges are distribution-related, not supply-related, and can be mitigated through generic prescribing, proactive stock verification, and awareness of readily available alternatives.

Equipping your practice with the right tools and information helps ensure your patients get treated quickly — even when their first-choice pharmacy is out of stock. Visit Medfinder for Providers to streamline medication availability checks in your workflow.

For additional clinical reference, see our guides on Cortisporin drug interactions and Cortisporin side effects. For cost-focused provider guidance, see how to help patients save money on Cortisporin.